Current Report Filing (8-k)
March 06 2017 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 6,
2017
INNOVUS PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-52991
|
90-0814124
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
9171
Towne Centre Drive, Suite 440
San Diego,
CA
|
|
92122
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17
CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 2.02 - Results of Operations and Financial
Condition
On
March 6, 2017, the Company issued a press release reporting our
financial results for the fourth quarter and full year ended
December 31, 2016. The full text of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release
issued March 6, 2017, reporting financial results for the fourth
quarter and full year ended December 31, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused
this Report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
INNOVUS PHARMACEUTICALS, INC.
|
|
|
Date: March
6, 2017
|
By:
|
/s/ Robert E.
Hoffman
Robert E. Hoffman
Executive Vice President, Chief Financial Officer
|
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
99.1
|
|
Press release
issued March 6, 2017, reporting financial results for the fourth
quarter and full year ended December 31, 2016
|